• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Alpha Tau Medical (DRTS) Is Up 6.6% After First Immunocompromised cSCC Patient Treated With Alpha DaRT

    Simply Wall St·07/17/2026 21:24:44
    语音播报
    • Alpha Tau Medical recently reported that it has successfully treated the first immunocompromised patient with recurrent cutaneous squamous cell carcinoma in its ADMIRE trial using intratumoral Alpha DaRT at Banner MD Anderson Cancer Center in Gilbert, Arizona.
    • This marks a rare, focused effort to evaluate a localized, repeatable therapy specifically for immunocompromised patients who are often excluded from cSCC trials and cannot safely receive standard checkpoint inhibitor immunotherapy.
    • We’ll now examine how this targeted move into treating immunocompromised cSCC patients shapes Alpha Tau’s broader investment narrative.

    Capitalize on the AI infrastructure supercycle with our selection of the 53 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

    What Is Alpha Tau Medical's Investment Narrative?

    For Alpha Tau, being a shareholder really comes down to believing that Alpha DaRT can translate its broad clinical footprint into a viable business before the cash burn and dilution pressures bite too hard. The stock has already rerated sharply, so near term, the key catalysts remain data readouts from the ReSTART pivotal cSCC trial, continued progress in glioblastoma and pancreatic programs, and execution of the Tolmar alliance in prostate cancer. The ADMIRE milestone fits into this by quietly expanding the addressable cSCC opportunity into a high‑need immunocompromised segment and reinforcing the platform’s versatility, but with just one patient treated so far, it is more about strengthening the long‑term story than shifting the immediate valuation debate. The biggest risks still sit around trial outcomes, timelines, funding and a rich price to book.

    Yet there is one funding and dilution risk here that investors should not overlook.

    The analysis detailed in our Alpha Tau Medical valuation report hints at an inflated share price compared to its estimated value.

    Exploring Other Perspectives

    DRTS 1-Year Stock Price Chart
    DRTS 1-Year Stock Price Chart

    The single US$14.20 fair value estimate from the Simply Wall St Community shows one retail view, while the company’s rich valuation, cash burn and trial dependency highlight why other investors may see the risk‑reward very differently.

    Explore another fair value estimate on Alpha Tau Medical - why the stock might be worth as much as $14.20!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Contemplating Other Strategies?

    Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.